Annual Drug Patent Expirations for DUTREBIS
Dutrebis is a drug marketed by Merck Sharp Dohme and is included in one NDA. There are five patents protecting this drug.
This drug has forty-six patent family members in thirty-four countries.
The generic ingredient in DUTREBIS is lamivudine; raltegravir potassium. Additional details are available on the lamivudine; raltegravir potassium profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
